EP Patent

EP3714884A1 — Medical uses for benzodiazepines with a particular eeg pattern

Assigned to Paion UK Ltd · Expires 2020-09-30 · 6y expired

What this patent protects

The present invention relates to a benzodiazepine or pharmaceutically acceptable salt thereof for use in inducing and/or maintaining a MOAA/S score of ≤ 1 in a human patient selected from an infant, a child and a patient with a cognitive impairment that is at least mild cognitive…

USPTO Abstract

The present invention relates to a benzodiazepine or pharmaceutically acceptable salt thereof for use in inducing and/or maintaining a MOAA/S score of ≤ 1 in a human patient selected from an infant, a child and a patient with a cognitive impairment that is at least mild cognitive impairment, or for use in inducing and/or maintaining a MOAA/S score of ≤ 1 in a patient without causing brain damage, wherein the benzodiazepine or salt is defined by having the property of leading to one or more particular characteristics of an electroencephalogram of a human reference subject in case said benzodiazepine or salt is administered to said reference subject to induce and/or maintain a MOAA/S score of ≤ 1.

Drugs covered by this patent

Patent Metadata

Patent number
EP3714884A1
Jurisdiction
EP
Classification
Expires
2020-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Paion UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.